OOIR: Observatory of International Research

Papers

(The TQCC of CTS-Clinical and Translational Science is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-07-01 to 2026-07-01.)

Article	Citations
Gene polymorphism and prediction of toxicity to platinum‐based chemotherapy in patients with gynecologic cancer	643
Intradermal substance P as a challenge agent in healthy individuals	233
The impact of skin color and tone on histamine iontophoresis and Doppler flowmetry measurements as a pharmacodynamic biomarker	161
Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection	128
Patient, industry, and regulatory perspective on antibody‐drug conjugates dose optimization	87
	82
Issue Information	82
ST2 and CSF‐1 as potential druggable targets of inflammatory bowel diseases: Results from two‐sample Mendelian randomization study	72
A Patient Centric Model for Vaso‐Occlusive Crises in Sickle Cell Disease—Outcomes of a Consensus Exercise Conducted Across Patients and Experts	67
Developing a clinical research infrastructure embedded in an academic medicine center that equitably supports future clinician scientists	67
Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community	59
Pharmacokinetics and Toxicity of Dimethylacetamide and Its Metabolite in Pediatric Patients Treated With High Dose Intravenous Busulphan	57
Clinician Satisfaction With Pharmacogenomics Clinical Services at a Multistate Health System	54
	51
Issue Information	51
First, Do No Harm: Addressing AI's Challenges With Out‐of‐Distribution Data in Medicine	49
Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications	46
The Effect of Diabetes Medication on the Scores of the GNRI and CONUT Nutritional Indices: Cross‐S	43
Expanding regulatory science: Regulatory complementarity and reliance	42
Japanese Phase 1 Study for Global Development of Anti‐TL1A Antibody PF‐06480605: A Randomized, Placebo‐Controlled, Single‐Ascending Dose Study	42
Nontraditional Factors Influencing Cardiovascular Disease Risk: Correlation Among Framingham Risk Score, Body Composition Index, and Sleep‐Breathing Monitoring Index	39
From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry	39
CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin	39
Issue Information	39
Clinical and Economic Impact of Expanded TPMT Testing to Prevent Thiopurine‐Induced Myelosuppression in Australia: A Budget Impact Analysis	36

Glucocorticoid‐Induced Tumor Necrosis Factor Receptor Ligand: Correlation and Therapeutic Potential for Cognitive Impairment in Temporal Lobe Epilepsy	35
Risk factors for the development of sepsis in patients with cirrhosis in intensive care units	33
Integrative Use of Ningmitai Capsule and Cefoxitin in Treating Post‐Ureteroscopic Lithotripsy Stent‐Related Urinary Tract Infections	32
Pharmacogenetics of Mycophenolic Acid in Patients of African Descent: Underrepresentation of African Data	31
Ubrogepant Plasma and Cerebrospinal Fluid Exposures in Participants With a History of Migraine: Findings From a Phase 1b Open‐Label Trial	30
Bridging Implementation Gaps in Digital Health: A Translational Research Imperative for Equitable Healthcare Innovation	30
A comprehensive Thai pharmacogenomics database (TPGxD‐1): Phenotype prediction and variants identification in 942 whole‐genome sequencing data	30
Lexicon for blood‐based early detection and screening: BLOODPAC consensus document	30
Cerebrospinal Fluid and Plasma Concentrations of Atogepant in Humans	29
Simulated Y‐Site Compatibility of Calcium Gluconate and Benzylpenicillin With Maintenance Fluid Used in Neonatal Intensive Care Unit	29
First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome	27
Radiolabelled Cyclodextrins for the Positron Emission Tomography Imaging of Breast Cancer: Preclinical Perspectives	26
Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants	26
Utilization of Machine Learning Approaches for Drug Clearance Prediction and Population Pharmacokinetic Covariate Analysis	26
Surrogate Endpoints in Pivotal Clinical Trials for Drug Approval in Japan Compared to the United States	26
Generalizability in real‐world trials	26
Informing Dose for Pediatric Rare Diseases—A Survey of Recent Orphan Drugs Approvals	26
Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling Authority	26
Real‐world evidence to support regulatory submissions: A landscape review and assessment of use cases	25
Recommended Clinical Context and Patient Context Data Elements for Liquid Biopsy Data Submitted to Data Repositories and Data Commons	24
Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study	24
Efficacy and safety of tofacitinib in rheumatoid arthritis: Nine years of real‐world data	24
Prevalence of actionable pharmacogenetic variants and high‐risk drug prescriptions: A Swiss hospital‐based cohort study	24
Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry – Informing optimal antiplatelet strategies	23
Concentration–Response Analysis of the Combination of Pyronaridine and Piperaquine on Corrected QT Interval From a Randomized, Double‐Blind, Placebo‐	23
Emapalumab in Patients With Macrophage Activation Syndrome Associated With Still's Disease: A Population Pharmacokinetic/Pharmacodynamic Analysis	23
Diabetes Knowledge and Medication Adherence Among High‐Risk Type 2 Diabetic Patients in a Rural Area in Vietnam: A Cross‐Sectional Study	23
Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3‐internal‐tandem‐duplication‐positive acute myeloid leukemia	22
Gossypol improves myocardial dysfunction caused by sepsis by regulating histone acetylation	22
Feasibility study for a fully decentralized clinical trial in participants with functional constipation symptoms	22
	21
Risk Factors Analysis of Cutaneous Adverse Drug Reactions Caused by Targeted Therapy and Immunotherapy Drugs for Oncology and Establishment of a Prediction Model	21
Safety and Efficacy of HexaBody ‐ DR5 / DR5 in	21
Comprehensive analysis of clinical and biological features in Parkinson's disease associated with the LRRK2 G2019S mutation: Data from the PPMI study	21
Phase 1 Study Evaluating the Pharmacokinetics, Dose Proportionality, Bioavailability, and Tolerability of Subcutaneous Levothyroxine Sodium (XP‐8121)	20
First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor	20
Exploring the discrepancies between clinical trials and real‐world data: A small‐cell lung cancer study	20
Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants	20
A Randomized, Double‐Blind, Placebo‐Controlled Phase 1 Study of Adiponectin Agonist ( PEG )‐ BHD1028	20
Pharmacokinetics and Safety of Pelacarsen, a GalNAc ₃ ‐Conjugated Antise	20
Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma	20
Effect of Whole‐Brain Radiotherapy Dose on the Occurrence of Otitis Media and Mastoiditis in Patients With Lung Cancer With Brain Metastasis	19
Parkinson's disease: Still waiting for a cure	19
Issue Information	19
Human radiolabeled mass balance studies supporting the FDA approval of new drugs	19
Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors	19
Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma Using Miriplatin Without the Need for Hydration	18
Cardiovascular risk of urate‐lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan	18
Comparing machine learning and deep learning models to predict cognition progression in Parkinson's disease	18
Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact	18

Issue Information	18
Assessment of QT Interval Prolongation Using Concentration– QT Modeling for Iptacopan, an Oral Com	18
Colonic Tissue Expression of MAdCAM ‐1 Is Not Predictive of Vedolizumab Responsiveness in Inflammatory Bowel Disease	18
Evaluation of Drug–Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Heal	18
Effect of Selective Serotonin Reuptake Inhibitors on Coagulation: Fact or Fiction?	17
Lidocaine as an anti‐arrhythmic drug: Are there any indications left?	17
Predictors of Clinical Trial Participation Among Older U.S. Adults With Multimorbidity: A Cross‐Sectional Survey	17
Pediatric CYP2D6 metabolizer status and post‐tonsillectomy nausea and vomiting after ondansetron	17
Real‐world evidence in the cloud: Tutorial on developing an end‐to‐end data and analytics pipeline using Amazon Web Services resources	17
Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study	17
Use cases of registry‐based randomized controlled trials—A review of the registries' contributions and constraints	17
Hesitant adopters: An examination of hesitancy among adults in Arkansas who have taken the COVID‐19 vaccine	17
The Role of Candidate Polymorphisms in Drug Transporter Genes on High‐Dose Methotrexate in the Consolidation Phase of the AIEOP‐BFM ALL 2009 Protocol	17
A Tutorial and Use Case Example of the eXtreme Gradient Boosting (XGBoost) Artificial Intelligence Algorithm for Drug Development Applications	17
Real‐world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community‐based cancer center	16
The Inflammatory Response in the Murine Ovalbumin‐Induced Skin Inflammation Model Is Robust Despite Major Gut Microbiota Differences	16
Issue Information	16
Repurposing Purine Analog Antivirals to Modulate Serum Uric Acid: Evidence From Real‐World Data	16
	16
The Dorsal Forearm as a Novel Target for Intramuscular Injections: Clinical Pharmacokinetic Results With Naloxone	16
Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science	16
Transcriptomic Profiling of Cutaneous Melanoma Metastases Treated With Microwave Ablation—Pilot Study	16
	16
Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A /P‐gp Modulators	16
What motivates people with type 2 diabetes mellitus to participate in clinical trials from home?	15
A Multicenter Randomized Controlled Study on Pharmacokinetic‐Guided Vancomycin Use in Children With Severe Infections	15
Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase‐4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas	15
Integrating real‐world data and machine learning: A framework to assess covariate importance in real‐world use of alternative intravenous dosing regimens for atezolizumab	15
A Survey Study of Roadblocks in Translational Science	15
Mass Balance and Metabolism of ¹⁴ C ‐Atogepant in Healthy Male Participa	15
Issue Information	15
Issue Information	15
Engaging student opinions on vaccine development innovation: Experiences from a “Shark Tank” project	15
PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies	15
Pharmacokinetic evaluation of radiolabeled intraocular anti‐CLEC14a antibody in preclinical animal species and application in humans	15
Issue Information	15
Issue Information	15
A First‐In‐Human Phase 1 Study to Evaluate the Safety and Tolerability of LEM‐S401, a Novel siRNA‐DegradaBALL Drug Targeting CTGF in Healthy Adul	15
Prediction of molecular phenotypes for novel SCN1A variants from a Turkish genetic epilepsy syndromes cohort and report of two new patients with recessive Dravet syndrome	15
Insights From a User Experience‐Focused Virtual Study on the Feasibility and Challenges of Decentralized Clinical Trials	14
Model‐informed precision dosing of teicoplanin for the rapid achievement of the target area under the concentration‐time curve: A simulation study	14
Impact of Pharmacokinetic Gene Polymorphisms on Statin‐Induced Myotoxicity in Thai Patients Treated With Simvastatin	14
Free heme and hemopexin in acute kidney injury after cardiopulmonary bypass and transient renal ischemia	14
Academia and industry agreement on a feasibility tool for first‐time‐in‐human clinical trial units	14
First‐in‐Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin‐S Inhibitor, in Healthy Adult Subjects	14
Issue Information	14
Preimmunization of SPF Mice With Capsid Virus‐like Particle Has no Effect on CD8 ⁺	14
Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma	14
Tutorial Drug–Drug Interactions	14
Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta‐analysis	14
Penetration of linezolid and tedizolid in cerebrospinal fluid of mouse and impact of blood–brain barrier disruption	14
Ascites affects the benefit of carvedilol on patients with liver cirrhosis and esophageal and gastric varices	13
Optimizing expert and patient input in pediatric trial design: Lessons learned and recommendations from a collaboration between conect4children and European Patient‐CEntric ClinicAl TRial PLatforms	13
	13
Prevotella bivia Influences Antiretroviral Pharmacokinetics and Viral Replication in an Ex Vivo Vaginal Tissue Model	13
Dupilumab: Mechanism of action, clinical, and translational science	13
Association between statin use and dry eye disease in patients with hyperlipidemia: A population‐based retrospective cohort study	13
Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants	13
Preclinical assessment of drug–drug interaction of fb‐PMT, a novel anti‐cancer thyrointegrin αvβ3 antagonist	13
Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A	13
Machine learning framework to predict pharmacokinetic profile of small molecule drugs based on chemical structure	13
Characterization of Drug–Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS‐CoV‐2, in Healthy Participants	13
Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach	13
Artificial intelligence in rare disease diagnosis and treatment	13
Issue Information	13
Comparison of glutaminase and cancer antigen 125 for distinguishing benign and malignant ovarian tumors	13
Key Stakeholders' Knowledge, Opinions, and Interests on Real‐World Evidence in the Regulatory Process—Results of an EU ‐Wide Survey	13
Model‐Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer	13
The “One‐Step” approach for QT analysis increases the sensitivity of nonclinical QTc analysis	13
CYP2C83 and 4 define CYP2C8 phenotype: An approach with the substrate cinitapride	13
Response to “DPYD genotyping panels: Impact of population diversity”	13
Trial of Preemptive Pharmacogenetic Testing in Underserved Patients ( TOPP UP ): Study Framework and Baseline Characteristics of Randomized Controlle	12
Safety, pharmacokinetics, and pharmacodynamics of ART‐648, a PDE4 inhibitor in healthy subjects: A randomized, placebo‐controlled phase I study	12
A drug‐disease model for predicting survival in an Ebola outbreak	12
Leveraging patient‐centric sampling for clinical drug development and decentralized clinical trials: Promise to reality	12
Evaluation of potential drug–drug interactions with medical cannabis	12
Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long‐acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double‐blind, p	12
Updated DPYDHapB3 haplotype structure and implications for pharmacogenomic testing	12
Physiologically based absorption modeling to predict the bioequivalence of two apixaban formulations	12
Association between aortic calcification and cytokine levels in patients with peripheral artery disease	12

Application of Machine Learning for Predicting Progression‐Free and Overall Survival in Patients With Renal Cell Carcinoma	12
Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open‐label, multiple‐dose study	12
Prediction of Cisplatin‐Induced Acute Kidney Injury Using an Interpretable Machine Learning Model and Electronic Medical Record Information	12
Feasibility of preemptive pharmacogenetic testing and improvement of medication treatment satisfaction among medically underserved patients	12
Critical Roles for Modeling and Simulation and Real‐World Evidence to Inform Challenges in Clinical Trial Diversity Planning	12
Correction to “Enhanced Clearance of HIV ‐1 Broadly Neutralizing Antibody VRC07 ‐523‐	12
Proposing a framework to quantify the potential impact of pharmacokinetic drug–drug interactions caused by a new drug candidate by using real world data about the target patient population	12
Effect of carrot intake on glucose tolerance, microbiota, and gene expression in a type 2 diabetes mouse model	12
A Patient‐Derived 3D Cyst Model of Polycystic Kidney Disease That Mimics Disease Development and Responds to Repurposing Candidates	12
Anticoagulant therapy in COVID‐19: A narrative review	12
Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study	12
An overview of drug‐induced sodium channel blockade and changes in cardiac conduction: Implications for drug safety	12
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT‐787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial	11
	11
Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro	11
Issue Information	11
How AI Transforms Regulatory Submission: Current Clinical Implementation and Future Prospects	11
Association between serum albumin to serum creatinine ratio and mortality risk in patients with heart failure	11
Issue Information	11
Informing Implementation Strategies for Pharmacogenomics in Cancer: Development of Survey Tools for Healthcare Professionals and Consumers	11
No drug–drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants	11
Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose‐escalation phase I study	11
Use of Biomarkers in Drug Development for Regulatory Purposes	11
Subtyping treatment response of tirofiban in acute ischemic stroke based on neuroimaging features	11
	11
Clinical Pharmacology Approaches to Predict Efficacy of Monoclonal Antibodies Against Emerging SARS ‐ CoV	11
Potential biomarkers for fatal outcome prognosis in a cohort of hospitalized COVID ‐19 patients with pre‐existing comorbidities	11
Postmarket safety communications on drugs approved in Japan: A 25‐year analysis	11
Generic substitution of amlodipine is not associated with increased risk of mortality or adverse cardiovascular events: An observational cohort study	11
Age‐related off‐label drug prescribing in pediatric patients in South Korea and consistency of labeling compared to the United States, Europe, and Japan	10
High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID ‐19 Treatment	10
Association of Vancomycin Plus Piperacillin‐Tazobactam With Acute Kidney Injury: Differentiating Pseudo‐Injury From True Nephrotoxicity	10
An exploratory machine learning approach to identify placebo responders in pharmacological binge eating disorder trials	10
Remimazolam versus propofol in combination with esketamine for surgical abortion: A double‐blind randomized controlled trial	10
A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens	10
A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence	10
Differential effects of metformin‐mediated BSEP repression on pravastatin and bile acid pharmacokinetics in humans: A randomized controlled trial	10
Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors	10
AAV Gene Therapy Drug Development and Translation of Engineered Ocular and Neurotropic Capsids: A Systematic Review Using Natural Language Processing	10
Issue Information	10
Atogepant: Mechanism of action, clinical and translational science	10
Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole	10
	10
Proteomics Used in Identifying Novel Correlates of Disease in Pediatric Metabolic Dysfunction‐Associated Steatotic Liver Disease	10
Decentralized Clinical Trials in the Era of Real‐World Evidence: A Statistical Perspective	10
Pharmacokinetics and Safety of Fixed‐Dose Versus Separate Enavogliflozin/Gemigliptin Combinations, and Food Effect on Enavogliflozin in Healthy Korean Subjects	10
Safety, Tolerability, and Pharmacokinetics of NIM‐1324 an Oral LANCL2 Agonist in a Randomized, Double‐Blind, Placebo‐Controlled Phase I Clinical Trial	10
Regulation of exosomes as biologic medicines: Regulatory challenges faced in exosome development and manufacturing processes	10
A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens	10
Leveraging [ ¹⁸ F ]F‐Piflufolastat PET	10
Severe Thiopurine‐Induced Myelosuppression in a Pediatric Acute Lymphoblastic Leukemia Patient With the NUDT15 1/6 Genotype: A Brief Report	10
Standardization, Education, and Resourcing: The Way Forward for Implementing Polygenic Risk Scores in Hereditary Breast and Ovarian Cancer	10
Clinical Characteristics, Molecular Diagnosis, and Drug Resistance Profiles of Nontuberculous Mycobacteria Infections: A Retrospective Analysis Using PCR	10
Controlled oxygenated rewarming as novel end‐ischemic therapy for cold stored liver grafts. A randomized controlled trial	9
Global harmonization of immediate‐release solid oral drug product bioequivalence recommendations and the impact on generic drug development	9
Issue Information	9
Application of Machine Learning to Discriminate Photoreceptor Cell Species in Xenotransplanted Chimeric Retinas	9
A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS‐CoV‐2(−)/(+) populations	9
Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review	9
Translational Pharmacokinetic‐Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI ‐6148 for the Treatment of Cutaneous Leishmanias	9
Surfing the T Wave: A Primer on ECG T Wave Morphologies Encountered in Clinical Trials and Impact on the QT Interval and Patient Safety	9
Pioneering a Hybrid Decentralized Clinical Trial in South Korea: Assessing Feasibility, Data Integrity, and Participant Perceptions	9
First‐In‐Human, Randomized, Placebo‐Controlled, SAD and MAD Trial to Evaluate Safety, Tolerability, and PK/PD Modeling of Potravitug in Healthy Adults	9
	9
Pharmacogenomic and Clinical Predictors of Deferasirox Response in Transfusion‐Dependent Thalassemia Identified Using Whole‐Genome Sequencing	9
Opportunities and challenges of 5G network technology toward precision medicine	9
Population‐Based Modeling to Predict Human PK / PD of TAK	9
Exploratory Evaluation of Solanidine as an Endogenous Marker for CYP2D6 ‐Mediated Drug–Drug–Gene Interactions of Venlafaxine in Koreans	9
Large‐Scale Analysis of Age and Sex Effects on Corrected QT and JT Intervals: Insights From Hospital‐Based Controls and Moxifloxacin‐Treated Cases	9
Pharmacokinetics of Bocidelpar, ASP0367, in Renal and Hepatic Impairment: Results From Two Phase 1 Studies	9
In Vitro Diagnostics for SARS ‐ CoV ‐2 Infection Authorized in the United States and Approved in J	9
Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like re	9
Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions	9
Drug Interaction PBPK Modeling: Review of the Literature Exposes the Need for Increased Verification of Model Inputs and Outputs as Part of Credibility Assessment	9
Optimizing a therapy for opiate use disorders: Characterizing ondansetron pharmacokinetics in blood and brain	8
Pharmacokinetic comparison of subcutaneously administered CT‐P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants	8
Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism	8
Effects of Nacubactam and Its Metabolites on QTc Interval: A Pooled Analysis of Two Randomized Phase 1 Studies	8
Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data	8
Pharmacokinetics and Safety of Polaprezinc Granules Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions	8
Umbilical cord blood–derived exosomes from healthy term pregnancies protect against hyperoxia‐induced lung injury in mice	8
BLOODPAC: Collaborating to chart a path towards blood‐based screening for early cancer detection	8
Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double‐blind placebo‐controlled cross‐over study	8
Tutorial: Microbiome studies in drug metabolism	8
Integrating Sustainability Pillars Into Trial Design Decision‐Making: Results of an International Survey	8
Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole	8
Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer	8
Pacific Blue Derivatives of Paclitaxel as Fluorescent Probes of OATP1B‐Type Transporters	8
Developing a mechanistic translational PK/PD model for a trifunctional NK cell engager to predict the first‐in‐human dose for acute myeloid leukemia	8
Dicloxacillin and Flucloxacillin Inhibit Hepatic Uptake Transporters—In Vitro Investigations and Physiologically Based Pharmacokinetic Modeling	8
Thai pharmacogenomics database −2 (TPGxD‐2) sequel to TPGxD‐1, analyzing genetic variants in 26 non‐VIPGx genes within the Thai population	8
Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer	8
The expanding universe of NUTM1 fusions in pediatric cancer	8
Association between psychomotor function and ALDH2 genotype after consuming barley shochu: A randomized crossover trial	8
Association of Protocol Design‐Related Factors With Enrollment Duration in Clinical Trials	8